Search research articles
Contact Us
Filters
Showing results (1-10 of 81) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
January 2, 2021
Facebook groups for alternative treatments for cancer: advertising masquerading as community support
Tristan M Sissung, William D Figg
Cancers
|
March 10, 2022
Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted
Tristan M Sissung, William D Figg
Family & Community Health
|
April 6, 2022
Commentary: Electronic Nicotine Delivery Systems: Seeing Through the Clouds
Tristan M Sissung, William D Figg
The Lancet. Oncology
|
February 3, 2020
Stem cell clinics: risk of proliferation
Tristan M Sissung, William D Figg
Cancer Biology & Therapy
|
September 8, 2012
Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer
Elias Pratt, Tristan M Sissung, William D Figg
Urology
|
August 28, 2016
Erratum to: Association of a CYP17 Polymorphism With Overall Survival in Caucasian Patients With Androgen-independent Prostate Cancer
Tristan M Sissung, David J Venzon, William D Figg
Cancer Biology & Therapy
|
October 20, 2009
A genomic strategy for predicting androgen receptor activity in prostate tumors
Johann G Jonsson, Tristan M Sissung, William D Figg
The Lancet. Oncology
|
February 5, 2019
Insulin potentiation therapy for cancer?
Tristan M Sissung, Keith T Schmidt, William D Figg
Cancer Biology & Therapy
|
January 29, 2011
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents
Cody J Peer, Tristan M Sissung, William D Figg
Cancer Biology & Therapy
|
July 6, 2017
Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients
Ralph J Hauke, Tristan M Sissung, William D Figg
Page
of 9
Search research articles
Search
Showing results (1-10 of 81) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
January 2, 2021
Facebook groups for alternative treatments for cancer: advertising masquerading as community support
Tristan M Sissung, William D Figg
Cancers
|
March 10, 2022
Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted
Tristan M Sissung, William D Figg
Family & Community Health
|
April 6, 2022
Commentary: Electronic Nicotine Delivery Systems: Seeing Through the Clouds
Tristan M Sissung, William D Figg
The Lancet. Oncology
|
February 3, 2020
Stem cell clinics: risk of proliferation
Tristan M Sissung, William D Figg
Cancer Biology & Therapy
|
September 8, 2012
Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer
Elias Pratt, Tristan M Sissung, William D Figg
Urology
|
August 28, 2016
Erratum to: Association of a CYP17 Polymorphism With Overall Survival in Caucasian Patients With Androgen-independent Prostate Cancer
Tristan M Sissung, David J Venzon, William D Figg
Cancer Biology & Therapy
|
October 20, 2009
A genomic strategy for predicting androgen receptor activity in prostate tumors
Johann G Jonsson, Tristan M Sissung, William D Figg
The Lancet. Oncology
|
February 5, 2019
Insulin potentiation therapy for cancer?
Tristan M Sissung, Keith T Schmidt, William D Figg
Cancer Biology & Therapy
|
January 29, 2011
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents
Cody J Peer, Tristan M Sissung, William D Figg
Cancer Biology & Therapy
|
July 6, 2017
Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients
Ralph J Hauke, Tristan M Sissung, William D Figg
Page
of 9